Allogeneic Mesenchymal Stem Cell Therapy Promotes Osteoblastogenesis and Prevents Glucocorticoid-Induced Osteoporosis

This study revealed the therapeutic potential of systemically infused, genetically unmodified allogeneic MSCs in glucocorticoid-induced osteoporosis. The donor MSCs inhabited recipient bone marrow and promoted osteoblastogenesis. The therapeutic effects were based on maintenance of bone formation. These results provide important information regarding cell-based anabolic therapy for glucocorticoid-induced osteoporosis and uncover previously unrecognized mesenchymal stem cell behaviors following a homing event. The current study also indicates that minimizing the time of cell culture confers an advantage for increasing transplanted mesenchymal stem cells to the targeted organ to promote therapeutic effects.

Source: Stem Cells Translational Medicine - August 23, 2016 Category: Stem Cells Authors: Sui, B., Hu, C., Zhang, X., Zhao, P., He, T., Zhou, C., Qiu, X., Chen, N., Zhao, X., Jin, Y. Tags: Tissue Engineering and Regenerative Medicine, Mesenchymal Stem Cells Source Type: research